OAKLAND, Calif., March 2 /PRNewswire/ -- A new study in the online issue of Annals of Internal Medicine has found that cholesterol medications can work well among certain HIV patients who are at risk for cardiovascular disease.
Though HIV patients are at higher risk for cardiovascular disease in part due to lipid abnormalities that can occur with the use of certain antiretroviral therapies, researchers now have evidence that cholesterol medications work very well with these patients.
"This should be encouraging for patients and their providers," said the study's lead author, Michael Silverberg, Ph.D., MPH, a research scientist with the Kaiser Permanente Division of Research in Oakland, Calif. He explained that HIV patients getting cholesterol-reducing treatments such as statins get slightly less benefit on cholesterol levels from the treatment as patients without HIV infection; however, it is still a clinically significant benefit and side effects from the drugs occurred in very few patients.
In addition, say the researchers, the use of fibrates in combination with NNRTIs (a class of antiretroviral drugs) may be a good choice to manage triglyceride levels in HIV patients. Triglycerides are another fat in the blood that contributes to inflammation of the pancreas and may contribute to coronary disease, they explain.
The study, which appears in the March 3 online issue of the Annals of Internal Medicine, is the largest to date to compare the effectiveness and side effects of drugs to treat cholesterol problems in patients with and without HIV infection.
"The good news is lipid lowering therapy in HIV patients works - not quite as well as it does in patients without HIV, but close," explained Silverberg. Given the challenges for treating high cholesterol in HIV patients and the more aggressive target lipid goals for all patients, optimizing lifestyle factors such a
|SOURCE Kaiser Permanente|
Copyright©2009 PR Newswire.
All rights reserved